← Leaderboards
Albert Arias
Virginia Commonwealth University
$6,848,452
Attributed
$9,187,710
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2007–25$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,187,710 · 8
VA$0 · 1
By mechanism
UG1$3,080,593 · 1
R01$2,722,349 · 1
U01$1,597,923 · 1
K23$718,571 · 1
UG3$643,019 · 1
R21$407,232 · 1
Top collaborators
- Frederick Gerard Moeller6 shared
- James M Bjork1 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Frederick Gerard Moeller$65,095,599
- Caitlin Eileen Martin$3,787,017
- Amy June Jeffers$59,332
- Alaina Jaster$39,388
- James C Moore$1,223,728
Others in their field
Top investigators on “Placebos”
- Beth Baseler · Leidos Biomedical Research, Inc.$141,816,521
- Randall J Bateman · Washington University$134,290,222
- Elizabeth A Thom · George Washington University$115,751,620
- Eric Martin McDade · Washington University$96,859,497
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$93,253,804
- Georgia D Tomaras · Fred Hutchinson Cancer Center$93,253,804
Research focus
PlacebosFundingRandomizedPharmaceutical PreparationsAnticonvulsantsPilot ProjectsCravingMedicalClinical ResearchDoseAlcohol Use DisorderAlcohol Abuse TherapyLaboratoriesTopiramateHeavy DrinkingClinical TrialsParticipantResourcesAlcoholismCuesDrinkingAlcoholism TherapyAlcohol DependenceGrant
Grant awards (25)
Psilocybin-Assisted Treatment of Cocaine Use Disorder$643,019
UG3 · FY2025 · DA · contact PI
Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders$504,103
UG1 · FY2024 · DA
Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders$647,076
UG1 · FY2023 · DA
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder$1,597,923
U01 · FY2022 · DA
Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders$757,571
UG1 · FY2022 · DA
Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders$511,982
UG1 · FY2021 · DA
Olanzapine Augmentation in OUD Patients on Buprenorphine-Naloxone with Comorbid Symptoms of Serious Mental Illness (SMI): A Prospective Observational 8-week Pilot Study$147,343
UG1 · FY2021 · DA
Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders$512,518
UG1 · FY2020 · DA
Zonisamide Treatment of Alcohol Use Disorder: An Evaluation of Efficacy and Mechanism of Action$443,591
R01 · FY2020 · AA · contact PI
Zonisamide Treatment of Alcohol Use Disorder: An Evaluation of Efficacy and Mechanism of Action$545,286
R01 · FY2019 · AA · contact PI
Perampanel Treatment of Alcohol Use Disorder$184,359
R21 · FY2019 · AA · contact PI
Effectiveness of Zonisamide in the Treatment of Alcohol Dependent Veterans$0
I01 · FY2019 · VA · contact PI
Zonisamide treatment of alcohol use disorder: an evaluation of efficacy and mechanism of action$569,673
R01 · FY2018 · AA · contact PI
Perampanel Treatment of Alcohol Use Disorder$222,873
R21 · FY2018 · AA · contact PI
Effectiveness of Zonisamide in the Treatment of Alcohol Dependent Veterans$0
I01 · FY2018 · VA · contact PI
Zonisamide treatment of alcohol use disorder: an evaluation of efficacy and mechanism of action$573,862
R01 · FY2017 · AA · contact PI
Effectiveness of Zonisamide in the Treatment of Alcohol Dependent Veterans$0
I01 · FY2017 · VA · contact PI
Zonisamide treatment of alcohol use disorder: an evaluation of efficacy and mechanism of action$589,937
R01 · FY2016 · AA · contact PI
Effectiveness of Zonisamide in the Treatment of Alcohol Dependent Veterans$0
I01 · FY2016 · VA · contact PI
Alcohol Dependence: Pharmacotherapy, Pharmacogenetics, and Genetics$169,829
K23 · FY2013 · AA · contact PI
Alcohol Dependence: Pharmacotherapy, Pharmacogenetics, and Genetics$182,611
K23 · FY2012 · AA · contact PI
Alcohol Dependence: Pharmacotherapy, Pharmacogenetics, and Genetics$182,611
K23 · FY2011 · AA · contact PI
Alcohol Dependence: Pharmacotherapy, Pharmacogenetics, and Genetics$183,520
K23 · FY2010 · AA · contact PI
CLINICAL TRIAL: ZONISAMIDE VERSUS PLACEBO$12,690
M01 · FY2008 · RR · contact PI
ZONISAMIDE VERSUS PLACEBO$5,333
M01 · FY2007 · RR · contact PI